StreetAlpha.app
Home › Stocks › RLAY

Relay Therapeutics, Inc. (RLAY)

Healthcare
$16.12
▲ +1.32%
LAST CLOSE · NOV 20

Relay Therapeutics develops small molecule drugs for patients with cancer and genetic disease. It last closed at $16.12 on Nov 20, up 1.32% on the day. The next earnings report for RLAY is expected around Thu, Feb 25, 2027, after the close. For the quarter ended Sep 2026, RLAY reported EPS of -$0.37 on revenue of $0. Over its last 8 reports the stock moved an average of 6.5% the session after earnings. Over the last 12 months RLAY insiders bought $0 of stock on the open market and sold $130.7M, according to SEC Form 4 filings.

AI Auto Pilots
Is RLAY in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold RLAY.

Key Stats

Last 12 months
Results
Revenue
$10.3M
+23.9% vs a year ago
Net income
−$293.6M
−2837.0% margin
EPS (diluted)
−$1.50
Free cash flow
−$214.0M
−2067.8% margin
Valuation
Market cap
$3.6B
221.0M shares
P/E
–
No P/E while losing money
Price to sales
344.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$124.2M
At Sep 30
Shareholder equity
$819.0M
Shares outstanding
221.0M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $3.0M$3.0MFY2021FY2022: $1.4M$1.4MFY2022FY2023: $25.5M$25.5MFY2023FY2024: $10.0M$10.0MFY2024FY2025: $15.4M$15.4MFY2025

From RLAY's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
Feb 25
Estimated date · After the close
Reported EPS
-$0.37
Quarter ended Sep 2026
Year ago EPS
-$0.43
Same quarter last year
Revenue
$0
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.42Dec '24Mar 2025: -$0.46Mar '25Jun 2025: -$0.41Jun '25Sep 2025: -$0.43Sep '25Dec 2025: -$0.31Dec '25Mar 2026: -$0.41Mar '26Jun 2026: -$0.41Jun '26Sep 2026: -$0.37Sep '26Latest -$0.37
Revenue by quarter
Dec 2024: $0Dec '24Mar 2025: $7.7MMar '25Jun 2025: $677,000Jun '25Sep 2025: $0Sep '25Dec 2025: $7.0MDec '25Mar 2026: $3.0MMar '26Jun 2026: $350,000Jun '26Sep 2026: $0Sep '26Latest $0
How RLAY moved after its last 8 reports
Average move the session after a report ±6.5%
Nov 4, 2026After the close−5.7%
Aug 6, 2026After the close+0.1%
May 5, 2026After the close−0.6%
Feb 26, 2026After the close+12.0%
Nov 6, 2025After the close−7.3%
Aug 7, 2025After the close−7.7%
May 5, 2025After the close−5.1%
Feb 26, 2025After the close−13.3%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on RLAYStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on RLAY
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on RLAY

Technical Analysis

RLAY · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend

The stock is 12% below its 20 day and 12% below its 50 day average. It is 2% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 39). The nearest support is the Pivot at $15.87, and the nearest resistance the Pivot R1 at $16.57.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityNormal, 6.9%/day
Key levels
$21.2752 week high+31.9%
$18.75100 day average+16.3%
$18.1350 day average+12.5%
$18.0720 day average+12.1%
$17.47Swing high (Jun 2)+8.4%
$16.57Pivot R1+2.8%
$16.12Last close
$15.87Pivot−1.6%
$15.74200 day average−2.4%
$15.42Pivot S1−4.3%
$13.30Swing low (Jun 1)−17.5%
$6.2852 week low−61.0%
Indicators
RSI (14)39.40Weak, oversold below 30Neutral
MACD-0.47Below its signal lineBearish
Stochastic7.6Near the bottom of its rangeOversold
ADX (14)17.1No clear trend
Williams %R-83.6Oversold below −80, overbought above −20Oversold
CCI (20)-149.0Oversold below −100, overbought above 100Oversold
Rate of change−13.3%Change over 10 sessionsBearish
ATR (14)$1.11Typical daily range, 6.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for RLAY

What happened before

See how RLAY did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow RLAY usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How RLAY has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for RLAYHow many large options trades hit RLAY, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

RLAY Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●126 buying vs 115 selling
  • ▲Held by funds +2.9 pts
  • ●Funds holding -1
  • ▼Superinvestors: 1 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding261262−0.4%
In funds' top 101211+9.1%
Held by funds114.6%111.7%+2.9 pts
New / increased33 / 9349 / 114−22.7%
Reduced / sold out83 / 3264 / 30+22.3%
Put/call ratio0.287.62−96.3%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See RLAY institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

RLAY Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$130.7M34 sales · 5 insiders
10% of the selling was under pre-arranged trading plans.
2026-01 sold $724K2026-03 sold $178K2026-04 sold $305K2026-05 sold $228K2026-06 sold $5.7M2026-07 sold $1.5M2026-08 sold $117.8M2026-09 sold $1.4M2026-10 sold $1.3M2026-11 sold $1.5MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 19Sanjiv PatelPresident and CEOSale plan48,202$16.13$777K
Nov 18Thomas CatinazzoCFOSale plan32,717$16.51$540K
Nov 18Donald A BergstromPresident, R&DSale plan10,269$16.51$170K
Oct 28Thomas CatinazzoCFOSale1,469$18.62$27K
Oct 28Donald A BergstromPresident, R&DSale2,252$18.62$42K
Oct 28Peter RahmerSee remarksSale753$18.62$14K
Every insider buy and sale for RLAY over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See RLAY insider trades →

From SEC Form 4 filings by RLAY's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RLAY is in one of them and how their past RLAY trades turned out.

RLAY in the AI portfolios
Loading…

RLAY News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered RLAY in an article yet. Here's the latest on the wider market.

RLAY in the news

RLAY Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Aug 13
Who traded RLAY · since 2023
Latest 1 filing
$1K – $15KTraded Jul 12, 2023Filed Aug 13, 2023
PersonTypeAmountTradedFiledDelay
Dan GoldmanD · NYSell$1K – $15KJul 12, 2023Aug 13, 202332 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Relay Therapeutics

Relay Therapeutics is a biotechnology company based in Cambridge, Massachusetts, that develops small molecule drugs for patients with cancer and genetic disease. Its work centers on its Dynamo platform, which uses computational and experimental methods to study how proteins move and to design drugs for protein targets that conventional approaches have struggled to address. Its lead candidate, zovegalisib, is in clinical trials for breast cancer and for vascular anomalies. The company is still testing its therapies, so it does not yet sell medicines to patients.

Headquarters
Cambridge, MA
Founded
2016